Chen R, Xu J, Wang Y, Jiang B, Xu X, Lan Y, Wang J, Lin X Prevalence of sarcopenia and its association with clinical outcomes in heart failure: An updated meta-analysis and systematic review. Clin Cardiol. 2023 Mar;46(3):260-268. doi: 10.1002/clc.23970. Epub 2023 Jan 16.
Coles AH, Tisminetzky M, Yarzebski J, Lessard D, Gore JM, Darling CE, Goldberg RJ Magnitude of and Prognostic Factors Associated With 1-Year Mortality After Hospital Discharge for Acute Decompensated Heart Failure Based on Ejection Fraction Findings. J Am Heart Assoc. 2015 Dec 23;4(12):e002303. doi: 10.1161/JAHA.115.002303.
Green CP, Porter CB, Bresnahan DR, Spertus JA Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000 Apr;35(5):1245-55. doi: 10.1016/s0735-1097(00)00531-3.
Liu C, Cheng KY, Tong X, Cheung WH, Chow SK, Law SW, Wong RMY The role of obesity in sarcopenia and the optimal body composition to prevent against sarcopenia and obesity. Front Endocrinol (Lausanne). 2023 Mar 1;14:1077255. doi: 10.3389/fendo.2023.1077255. eCollection 2023.
Niedziela JT, Hudzik B, Strojek K, Polonski L, Gasior M, Rozentryt P Weight loss in heart failure is associated with increased mortality only in non-obese patients without diabetes. J Cachexia Sarcopenia Muscle. 2019 Dec;10(6):1307-1315. doi: 10.1002/jcsm.12471. Epub 2019 Aug 9.
Savarese G, Lund LH Global Public Health Burden of Heart Failure. Card Fail Rev. 2017 Apr;3(1):7-11. doi: 10.15420/cfr.2016:25:2.
Sayer AA, Cruz-Jentoft A Sarcopenia definition, diagnosis and treatment: consensus is growing. Age Ageing. 2022 Oct 6;51(10):afac220. doi: 10.1093/ageing/afac220.
Yin J, Lu X, Qian Z, Xu W, Zhou X New insights into the pathogenesis and treatment of sarcopenia in chronic heart failure. Theranostics. 2019 May 31;9(14):4019-4029. doi: 10.7150/thno.33000. eCollection 2019.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.